Wreesmann Volkert B, Singh Bhuvanesh
Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Surg Oncol Clin N Am. 2008 Jan;17(1):1-35, vii. doi: 10.1016/j.soc.2007.10.013.
Thyroid cancer constitutes a progressive continuum of disease ranging from indolent well-differentiated carcinomas to aggressive poorly differentiated carcinomas and universally fatal anaplastic carcinomas. The wide divergence in clinical behavior is poorly predicted for by current clinicopathological factors. Moreover, therapeutic armentarium against aggressive thyroid cancers remains limited. Recent studies have identified a range of molecular alterations in thyroid cancers. Clinical implications of the molecular alterations include their utility in diagnostic evaluation, staging and targeted treatment. Continued molecular analysis of thyroid cancers promises to increase our understanding of its biologic behavior and is expected to have further impact on its clinical management.
甲状腺癌构成了一个疾病进展的连续谱，范围从惰性的高分化癌到侵袭性的低分化癌以及普遍致命的未分化癌。目前的临床病理因素对其临床行为的巨大差异预测能力较差。此外，针对侵袭性甲状腺癌的治疗手段仍然有限。最近的研究已经确定了甲状腺癌中的一系列分子改变。这些分子改变的临床意义包括它们在诊断评估、分期和靶向治疗中的应用。对甲状腺癌进行持续的分子分析有望增进我们对其生物学行为的理解，并有望对其临床管理产生进一步影响。
